Reduction of monocyte chemoattractant protein-1 and interleukin-8 levels by ticlopidine in TNF-α stimulated human umbilical vein endothelial cells

Chaur Jong Hu, Yueh Lun Lee, Neng Yao Shih, Yi Yuan Yang, Suparat Charoenfuprasert, Yu Shan Dai, Su Mei Chang, Yu-Hui Tsai, How Tseng, Chia Yu Liu, Sy Jye Leu

研究成果: 雜誌貢獻文章

8 引文 斯高帕斯(Scopus)


Atherosclerosis and its associated complications represent major causes of morbidity and mortality in the industrialized or Western countries. Monocyte chemoattractant protein-1 (MCP-1) is critical for the initiating and developing of atherosclerotic lesions. Interleukin-8 (IL-8), a CXC chemokine, stimulates neutrophil chemotaxis. Ticlopidine is one of the antiplatelet drugs used to prevent thrombus formation relevant to the pathophysiology of atherothrombosis. In this study, we found that ticlopidine dose-dependently decreased the mRNA and protein levels of TNF--stimulated MCP-1, IL-8, and vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs). Ticlopidine declined U937 cells adhesion and chemotaxis as compared to TNF-stimulated alone. Furthermore, the inhibitory effects were neither due to decreased HUVEC viability, nor through NF-kB inhibition. These results suggest that ticlopidine decreased TNF-induced MCP-1, IL-8, and VCAM-1 levels in HUVECs, and monocyte adhesion. Therefore, the data provide additional therapeutic machinery of ticlopidine in treatment and prevention of atherosclerosis.
期刊Journal of Biomedicine and Biotechnology
出版狀態已發佈 - 2009


ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Genetics
  • Molecular Biology
  • Health, Toxicology and Mutagenesis
  • Medicine(all)